AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and Processes
BromocriptineErgolinesProlactinomaHyperprolactinemiaDopamine AgonistsProlactinPituitary NeoplasmsPergolideLisurideHormone AntagonistsAcromegalyAntiparkinson AgentsDopamine AgentsGigantismGalactorrheaMetoclopramidePituitary ACTH HypersecretionHeart Valve DiseasesAmenorrheaFibrous Dysplasia, PolyostoticParkinson DiseaseAdenomaReceptors, DopamineReceptor, Serotonin, 5-HT2BFoxesLevodopaPimozideDomperidoneReceptors, Dopamine D2Heart ValvesLysergic AcidCyproheptadineEndocrine System DiseasesOctreotideAkinetic MutismAortic BodiesNocturnal Myoclonus SyndromeErgot Alkaloids11-HydroxycorticosteroidsLactationPregnancy Complications, NeoplasticAbortion, VeterinaryBromineOvarian Hyperstimulation SyndromePregnancyPetrosal Sinus SamplingPericarditis, Constrictive
PergolideProlactinDopamine agonists includeClomipheneErgoline dopaminePharmacodynamic antagonismPituitaryPuerperalProlactineMedicationsPlaceboGalactorrheaLactationDoseTabletsReceptorsLevelsEffectsChoiceHoursWomenDostinexHyperprolactinemiaProlactin-lowering effect of caQuinagolideAffinity for dopamineEfficacy of cabergolineDosesErgotAdministered to suppress lactationApomorphineProlactinomasNitroglycerin topicalDopamine receptorAgonistDecreasesPlaceboCannot tolerateHyperprolactinemicPatientsHyperprolactinaemiaSerum prolactin levelsTopicalAdversePillsDrugDecreaseTherapyCommonMothersNeed to takeStudyWeeklyRiskEffectEffectiveWeekRelease
Pergolide3
Prolactin9
  • Results of in vitro studies demonstrate that cabergoline exerts a direct inhibitory effect on the secretion of prolactin by rat pituitary lactotrophs. (nih.gov)
  • Cabergoline decreased serum prolactin levels in reserpinized rats. (nih.gov)
  • The prolactin-lowering efficacy of cabergoline was demonstrated in hyperprolactinemic women in two randomized, double-blind, comparative studies, one with placebo and the other with bromocriptine. (nih.gov)
  • cabergoline n=168), cabergoline produced a dose-related decrease in serum prolactin levels with prolactin normalized after 4 weeks of treatment in 29%, 76%, 74% and 95% of the patients receiving 0.125, 0.5, 0.75, and 1.0 mg twice weekly respectively. (nih.gov)
  • bromocriptine n=236 in the intent-to-treat analysis), prolactin was normalized in 77% of the patients treated with cabergoline at 0.5 mg twice weekly compared with 59% of those treated with bromocriptine at 2.5 mg twice daily. (nih.gov)
  • The prolonged prolactin-lowering effect of cabergoline may be related to its slow elimination and long half-life. (nih.gov)
  • cabergoline n=168), DOSTINEX produced a dose-related decrease in serum prolactin levels with prolactin normalized after 4 weeks of treatment in 29%, 76%, 74% and 95% of the patients receiving 0.125, 0.5, 0.75, and 1.0 mg twice weekly respectively. (drugs.com)
  • Medications used typically include something to disrupt prolactin secretion (either cabergoline or bromocriptine) in combination with prostaglandin (a hormone to induce uterine contractions and directly destroy the corpus luteum). (vin.com)
  • Bromocriptine and cabergoline were equally effective in lowering serum prolactin levels. (bvsalud.org)
Dopamine agonists include1
Clomiphene1
  • The main drugs used to overcome anovulation are clomiphene (Q10.6), tamoxifen (Q10.10), bromocriptine (Q10.11), metformin (Q10.12), and gonadotrophins (Q10.13). (2womenshealth.com)
Ergoline dopamine1
Pharmacodynamic antagonism2
  • bromocriptine decreases effects of nitroglycerin IV by pharmacodynamic antagonism. (medscape.com)
  • loxapine inhaled decreases effects of bromocriptine by pharmacodynamic antagonism. (medscape.com)
Pituitary2
Puerperal2
  • Bromocriptine also prevents puerperal fever caused by either breast engorgement or infection among women who do not nurse their newborn infants. (nih.gov)
  • Single dose cabergoline versus bromocriptine in inhibition of puerperal lactation: randomised, double blind, multicentre study. (e-lactancia.org)
Prolactine1
  • Low strength bromocriptine tablets (e.g. 2.5 mg) used as a prolactine inhibitor are classified in G02CB - Prolactine inhibitors. (whocc.no)
Medications1
Placebo1
  • A meta-analysis of published studies found evidence that bromocriptine is more effective than placebo for lactation suppression during the first week postpartum, but evidence is insufficient to comment on the acceptability of such therapy. (nih.gov)
Galactorrhea4
Lactation3
  • Bromocriptine is usually not used during breastfeeding because it suppresses lactation. (nih.gov)
  • 14 ] Cerebral angiopathy, stroke and seizures continue to be reported from countries where bromocriptine is still used to suppress lactation. (nih.gov)
  • An early double-blind study in 60 women who were less than 24 hours postpartum found bromocriptine to be as effective as diethylstilbestrol in suppressing postpartum lactation. (nih.gov)
Dose1
  • Over the 0.5-to-7 mg dose range, cabergoline plasma levels appeared to be dose-proportional in 12 healthy adult volunteers and nine adult parkinsonian patients. (nih.gov)
Tablets5
  • CABERGOLINE tablets contain cabergoline, a dopamine receptor agonist. (nih.gov)
  • Cabergoline tablets, for oral administration, contain 0.5 mg of cabergoline. (nih.gov)
  • DOSTINEX Tablets contain cabergoline, a dopamine receptor agonist. (drugs.com)
  • DOSTINEX Tablets, for oral administration, contain 0.5 mg of cabergoline. (drugs.com)
  • Bromocriptine used in parkinsonism is classified in this group (e.g. tablets of 5 mg and 10 mg). (whocc.no)
Receptors2
  • Cabergoline is a long-acting dopamine receptor agonist with a high affinity for D 2 receptors. (nih.gov)
  • Receptor-binding studies indicate that cabergoline has low affinity for dopamine D 1 , α 1 - and α 2 -adrenergic, and 5-HT 1 - and 5-HT 2 -serotonin receptors. (nih.gov)
Levels1
  • Following single oral doses of 0.5 mg to 1.5 mg given to 12 healthy adult volunteers, mean peak plasma levels of 30 to 70 picograms (pg)/mL of cabergoline were observed within 2 to 3 hours. (nih.gov)
Effects2
  • No adverse effects were noticed in 14 breastfed infants of mothers who were given oral bromocriptine 2.5 mg once daily for 3 days beginning on day 5 postpartum to decrease overproduction of milk. (nih.gov)
  • nitroglycerin IV increases effects of cabergoline by decreasing metabolism. (medscape.com)
Choice3
Hours1
  • The elimination half-life of cabergoline estimated from urinary data of 12 healthy subjects ranged between 63 to 69 hours. (nih.gov)
Women3
  • Restoration of menses occurred in 77% of the women treated with cabergoline, compared with 70% of those treated with bromocriptine. (nih.gov)
  • Thirty of the 40 women breastfed their infants, although it is not clear from the paper how many of the mothers continued to take bromocriptine during nursing. (nih.gov)
  • Restoration of menses occurred in 77% of the women treated with DOSTINEX, compared with 70% of those treated with bromocriptine. (drugs.com)
Dostinex6
  • The most common medications are bromocriptine (Parlodel TM ) and cabergoline (Dostinex TM ). (txfertility.com)
  • How does Cabergoline / Generic of Dostinex or Cabaser work? (rx2go.com)
  • Avec la cabergoline (Dostinex) et le pramipexole (Mirapex) ayant. (apsdg.org)
  • Dostinex et prise de poids, acheter stéroïdes en ligne médicaments de musculation. (apsdg.org)
  • Dostinex Sans Ordonnance (Cabergoline 0. (apsdg.org)
  • Gonflement des mains, des pieds ou des chevilles ou prise de poids rapide Dostinex et prise de poids, commander anabolisants stéroïdes en ligne paypal. (apsdg.org)
Hyperprolactinemia6
  • Cabergoline or Quinagolide versus Bromocriptine for Hyperprolactinemia with. (cadth.ca)
  • What is the clinical effectiveness of cabergoline versus bromocriptine as a first-line medication therapy for patients with hyperprolactinemia with or without prolactinoma? (cadth.ca)
  • Four systematic reviews (three with meta-analyses), one randomized controlled trial, and five non-randomized studies were identified regarding the clinical effectiveness of cabergoline versus bromocriptine as a first-line medication therapy for patients with hyperprolactinemia with or without prolactinoma. (cadth.ca)
  • However, a study by Budayr et al indicated that compared with the use of bromocriptine, treatment of hyperprolactinemia with cabergoline poses a greater risk of valvular regurgitation, although the regurgitation itself was found to be primarily mild. (medscape.com)
  • Kharlip et al looked at the recurrence of hyperprolactinemia after withdrawal of cabergoline therapy in 46 patients who had undergone long-term treatment with the drug. (medscape.com)
  • A successful breastfeeding has been described on about 30 cases of galactorrhea-prolactinoma-hyperprolactinemia that were treated with a daily dose of 2.5 to 5 mg of Bromocriptine with no effects noticed on the infants (Canales 1981, Cheng 1996, Verma 2006). (e-lactancia.org)
Prolactin-lowering effect of ca2
  • Maximum decrease of serum prolactin was -89.7% at 5 days, and the prolactin-lowering effect of cabergoline was still present at 14 days. (nih.gov)
  • The prolonged prolactin-lowering effect of cabergoline may be related to its slow elimination and long half-life. (nih.gov)
Quinagolide2
Affinity for dopamine2
  • Cabergoline has low affinity for dopamine D1, a1- and a2-adrenergic, and 5-HT1- and 5-HT2-serotonin receptors. (rx2go.com)
  • Receptor-binding studies indicate that cabergoline has low affinity for dopamine D 1 , α 1 - and α 2 -adrenergic, and 5-HT 1 - and 5-HT 2 -serotonin receptors. (nih.gov)
Efficacy of cabergoline2
  • We evaluated the efficacy of cabergoline, a new ergoline derivative, in blocking puerperal lactation in a group of women delivered by cesarean section. (nih.gov)
  • The prolactin-lowering efficacy of cabergoline was demonstrated in hyperprolactinemic women in two randomized, double-blind, comparative studies, one with placebo and the other with bromocriptine. (nih.gov)
Doses7
  • The dopamine agonist bromocriptine mesylate is often the initial drug of choice and may require high doses to achieve clinical improvement and shrinkage of prolactinomas. (medscape.com)
  • In a 4-week, double-blind, placebo-controlled study, treatment consisted of placebo or cabergoline at fixed doses of 0.125, 0.5, 0.75, or 1.0 mg twice weekly. (druglib.com)
  • A treatment scheme has been reported for mothers with hypergalactia that uses low doses of cabergoline to decrease milk supply. (nih.gov)
  • Serum prolactin levels collected on days 2, 3 and 4 of treatment were decreased significantly in all women who received cabergoline, but the decreases were not statistically different among the various doses. (nih.gov)
  • Following single oral doses of 0.5 mg to 1.5 mg given to 12 healthy adult volunteers, mean peak plasma levels of 30 to 70 picograms (pg)/mL of cabergoline were observed within 2 to 3 hours. (nih.gov)
  • We present the case of a patient treated for hyperprolactinaemia with weekly doses of cabergoline for 12 years. (rcpjournals.org)
  • Although high doses of cabergoline (used in other medical problems) have been associated with stiffening of heart valves, there has been NO evidence of this side-effect in the low doses used for the treatment of prolactinomas, even when used for a long time. (impendo.co.uk)
Ergot1
  • Cabergoline, an ergot derivative, is a long-acting DA agonist and is available in the United States. (medscape.com)
Administered to suppress lactation1
  • If Bromocriptine was eventually administered to suppress lactation but afterwards the mother is willing to resuming breastfeeding, the mother can do it immediately, trying to minimize the drug effect by frequent suckling the child to stimulate milk production. (e-lactancia.org)
Apomorphine1
  • Donnez-nous votre avis Classe : ANTIPARKINSONIEN DOPAMINERGIQUE (AGONISTE DE DOPAMINE) N04B-C01 : Bromocriptine, N04B-C02 : Pergolide, N04B-C03 : Dihydroergocryptine mésilate, N04B-C04 : Ropinirole, N04B-C05 : Pramipexole, N04B-C06 : Cabergoline, N04B-C07 : Apomorphine, N04B-C10 : Autre. (biam2.org)
Prolactinomas3
  • 10] Bromocriptine (BEC) is generally considered to be the agent of choice in the treatment of prolactinomas because of its long track record and safety. (medscape.com)
  • as como el nivel de evidencia para diagnosticar la hiperprolactinemia, tratar la hiperprolactinemia inducida por medicamentos y los prolactinomas en pacientes embarazadas o no embarazadas. (medigraphic.com)
  • 20. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas. (nih.gov)
Nitroglycerin topical1
  • nitroglycerin topical increases effects of cabergoline by decreasing metabolism. (medscape.com)
Dopamine receptor2
  • Cabergoline is a long-acting dopamine receptor agonist with a high affinity for D2 receptors. (rx2go.com)
  • Cabergoline tablets USP contain cabergoline, USP, a dopamine receptor agonist. (nih.gov)
Agonist3
  • The most effective and best tolerated dopamine agonist is cabergoline, at present. (springer.com)
  • Because of its established safety profile for the developing fetus, bromocriptine is the preferred dopamine agonist to use to facilitate ovulation and pregnancy. (springer.com)
  • In the UK, the most common dopamine agonist is called cabergoline. (impendo.co.uk)
Decreases2
  • cabergoline decreases effects of glyceryl trinitrate pr by pharmacodynamic antagonism. (medscape.com)
  • cabergoline decreases effects of nitroglycerin IV by pharmacodynamic antagonism. (medscape.com)
Placebo3
  • Seventeen women who did not wish to breastfeed received a placebo or a single oral dose of cabergoline 400 mcg or 600 mcg on day 2 or 3 postpartum. (nih.gov)
  • Thirty-two women who did not wish to breastfeed were given placebo or cabergoline 400, 600 or 800 mcg within 24 hours after delivery in a double-blind trial. (nih.gov)
  • A prospective, randomized, double-blinded study compared the effects of a single dose of cabergoline 0.5, 0.75 or 1 mg in 40 women each and to 20 women who received a placebo. (nih.gov)
Cannot tolerate1
Hyperprolactinemic2
  • The safety of cabergoline tablets has been evaluated in more than 900 patients with hyperprolactinemic disorders. (druglib.com)
  • The safety of cabergoline has been evaluated in approximately 1,200 patients with Parkinson's disease in controlled and uncontrolled studies at dosages of up to 11.5 mg/day which greatly exceeds the maximum recommended dosage of cabergoline for hyperprolactinemic disorders. (druglib.com)
Patients7
  • [ 18 ] At the beginning of the investigation, the study's patients were normoprolactinemic and had experienced tumor volume reduction after at least 2 years of treatment with cabergoline. (medscape.com)
  • They concluded that withdrawal of cabergoline is safe in patients meeting the criteria used in the study but that close follow-up with these patients is essential, particular in the first year after the drug's discontinuation. (medscape.com)
  • cabergoline n = 168), cabergoline produced a dose-related decrease in serum prolactin levels with prolactin normalized after 4 weeks of treatment in 29%, 76%, 74% and 95% of the patients receiving 0.125, 0.5, 0.75, and 1 mg twice weekly respectively. (nih.gov)
  • bromocriptine n = 236 in the intent-to-treat analysis), prolactin was normalized in 77% of the patients treated with cabergoline at 0.5 mg twice weekly compared with 59% of those treated with bromocriptine at 2.5 mg twice daily. (nih.gov)
  • Among patients with galactorrhea, this symptom disappeared in 73% of those treated with cabergoline compared with 56% of those treated with bromocriptine. (nih.gov)
  • Over the 0.5 to 7 mg dose range, cabergoline plasma levels appeared to be dose-proportional in 12 healthy adult volunteers and nine adult parkinsonian patients. (nih.gov)
  • Sometimes female patients need to take cabergoline or bromocriptine until they conceive and occasionally during pregnancy. (impendo.co.uk)
Hyperprolactinaemia1
  • A case of constrictive pericarditis during cabergoline treatment for hyperprolactinaemia. (nih.gov)
Serum prolactin levels1
Topical1
Adverse3
  • Cabergoline, in particular, probably is more effective and causes fewer adverse effects than bromocriptine. (medscape.com)
  • The incidence of the most common adverse events during the double-blind portion of the comparative trial with bromocriptine is presented in the following table. (druglib.com)
  • 4 - 8 ] The disadvantage of cabergoline is that it has a half-life of about 68 hours, which means that any adverse effects might persist for a prolonged period of time. (nih.gov)
Pills1
  • Bromocriptine and cabergoline are pills taken orally to treat abnormally high levels of the hormone prolactin, which can interfere with ovulation. (nih.gov)
Drug1
Decrease1
  • 1 , 2 ] A retrospective study of 225 women who received cabergoline postpartum had a maximum decrease in systolic blood pressure of 10.88 mm Hg at 20 to 24 hours after the dose. (nih.gov)
Therapy1
  • 12. Brain and optic chiasmal herniations into sella after cabergoline therapy of giant prolactinoma. (nih.gov)
Common1
Mothers1
Need to take1
Study1
  • Moreover, the adjusted odds ratio in the study for two or more valves with grade 2+ regurgitation was highest for cumulative cabergoline exposure of over 115 mg. (medscape.com)
Weekly1
  • A woman with acromegaly was treated with lanreotide Autogel 120 mg monthly, cabergoline 2 mg weekly and pegvisomant 80 mg weekly. (nih.gov)
Risk1
  • Monitor oxygen is unilateral or written action threshold, treatment in myopic children, to minimize risk above the acheter viagra en ligne. (yourbirthexperience.com)
Effect1
  • Since a possible dose-related effect was observed for nausea only, the four cabergoline treatment groups have been combined. (druglib.com)
Effective1
Week1
  • Cabergoline was stopped, and a week later she abruptly became aware that she was in debt and is currently seeking bankruptcy. (rcpjournals.org)
Release1
  • Cabergoline inhibits the release of growth hormone and prolactin by stimulating dopamine receptors in the brain. (studymoose.com)